CDXS vs GEVO vs BEAM vs TRMK vs NUVB

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus 18. 6% for Codexis, Inc. (CDXS). Trustmark Corporation (TRMK) offers the better valuation at 12. 1x trailing P/E (11. 5x forward), making it the more compelling value choice. Analysts rate Codexis, Inc. (CDXS) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Trustmark Corporation (TRMK) delivered a total return of +47.

6%, compared to -86. 7% for Codexis, Inc. (CDXS). Over 10 years, the gap is even starker: TRMK returned +127. 7% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Trustmark Corporation (TRMK) is the lower-risk stock at 0.

94β versus Codexis, Inc. 's 2. 31β — meaning CDXS is approximately 144% more volatile than TRMK relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 145% for Codexis, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus 18. 6% for Codexis, Inc. (CDXS). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 1. 9% for Trustmark Corporation. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Trustmark Corporation (TRMK) is the more profitable company, earning 20.

0% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 20. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRMK leads at 25. 5% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 157.

3% to $12. 40.

In this comparison, TRMK (2.

2% yield) pays a dividend. CDXS, GEVO, BEAM, NUVB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Trustmark Corporation (TRMK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94), 2. 2% yield, +127. 7% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TRMK: +127. 7%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDXS (Healthcare) and GEVO (Basic Materials) and BEAM (Healthcare) and TRMK (Financial Services) and NUVB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

TRMK pays a dividend while CDXS, GEVO, BEAM, NUVB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.